BlackRock Fund Advisors recently announced the acquisition of new stake in Humacyte Inc (NASDAQ:HUMA). The institutional investor has increased its shareholding in the Healthcare company by 4.97% to 4.15 million shares with purchase of 0.2 million shares. This fresh investment now brings its stake to 4.00% valued currently at $10.99 million. In addition, The Vanguard Group, Inc. raised its holdings by 49472.0 to 2.91 million shares. And Geode Capital Management LLC has lifted its position by 11.54% or 0.13 million shares – to 1.23 million shares.
With over 0.45 million Humacyte Inc (HUMA) shares trading Friday and a closing price of $2.88 on the day, the dollar volume was approximately $1.29 million. The shares have shown a negative half year performance of -0.69% and its price on 12/22/23 gained nearly 2.49%. Currently, there are 103.23M common shares owned by the public and among those 74.92M shares have been available to trade.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Insiders at the company have transacted a total of 20 times over the past 12 months, according to data filed with the U.S. Securities and Exchange Commission (SEC). 5 of these insider trades were purchases, accounting for 297,949 shares. Insider sales of the common stock occurred on 15 occasions, with total insider shares sold totaling 20,997,594 shares.
The top 3 mutual fund holders in Humacyte Inc are Vanguard Total Stock Market ETF, iShares Russell 2000 ETF, and Vanguard Extended Market Index Fu. Vanguard Total Stock Market ETF owns 1.62 million shares of the company’s stock, all valued at over $4.29 million. iShares Russell 2000 ETF bought 735.0 shares to see its total holdings expand to 1.49 million shares valued at over $3.96 million and representing 1.44% of the shares outstanding. Vanguard Extended Market Index Fu bought 21476.0 shares to bring its total holdings to over 0.78 million shares at a value of $2.06 million. Vanguard Extended Market Index Fu now owns shares totaling to 0.75% of the shares outstanding.
Shares of Humacyte Inc (NASDAQ: HUMA) opened at $2.85, up $0.04 from a prior closing price of $2.81. The company’s stock has a 5-day price change of -6.80% and 0.70% over the past three months. HUMA shares are trading 36.49% year to date (YTD), with the 12-month market performance up to 36.49% higher. It has a 12-month low price of $1.96 and touched a high of $5.60 over the same period. HUMA has an average intraday trading volume of 448.49K shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 4.25%, 15.51%, and -8.42% respectively.
Institutional ownership of Humacyte Inc (NASDAQ: HUMA) shares accounts for 15.98% of the company’s 103.23M shares outstanding. Mutual fund holders own 8.26%, while other institutional holders and individual stakeholders account for 9.82% and 7.75% respectively.
It has a market capitalization of $298.31M and a beta (3y monthly) value of 1.38. The earnings-per-share (ttm) stands at -$0.86. Price movements for the stock have been influenced by the stock’s volatility, which stands at 6.82% over the week and 6.90% over the month.
Analysts forecast that Humacyte Inc (HUMA) will achieve an EPS of -$0.25 for the current quarter, -$0.25 for the next quarter and -$0.97 for 2024. The lowest estimate earnings-per-share for the quarter is -$0.27 while analysts give the company a high EPS estimate of -$0.24. Comparatively, EPS for the current quarter was -$0.04 a year ago. Earnings per share for the fiscal year are expected to decrease by -804.10%, and 10.55% over the next financial year.
If you are looking to buy this stock, then you may note that the average analyst recommendation by 6 brokerage firm advisors rate Humacyte Inc (HUMA) as a “Strong Buy” at a consensus score of 1.33. Specifically, 5 Wall Street analysts polled rate the stock as a buy, while 1 of the 6 advise that investors “hold,” and 0 rated it as a “Sell.”
Looking at the support for the HUMA, a number of firms have released research notes about the stock. H.C. Wainwright stated their Buy rating for the stock in a research note on December 11, 2023, with the firm’s price target at $6.
